BNTC (Benitec Biopharma) EPS (Basic): $-0.93 (TTM As of Mar. 2026)


BNTC Benitec Biopharma Inc BNTC
34 GF Score
Price $13.07
View Full Analysis

What is Benitec Biopharma EPS (Basic)?

Benitec Biopharma BNTC -4.49% 34 EPS (Basic) is $-0.93 as of Mar. 2026. GuruFocus rates BNTC with a GF Score™ of 34/100.

Benitec Biopharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.24. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.93.

Benitec Biopharma's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.24. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.93.

Benitec Biopharma's EPS without NRI for the three months ended in Mar. 2026 was $-0.24. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.94.

During the past 3 years, the average EPS without NRI Growth Rate was 69.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 64.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Benitec Biopharma's highest 3-Year average EPS without NRI Growth Rate was 71.70% per year. The lowest was -4.10% per year. And the median was 36.30% per year.

Benitec Biopharma  (NAS:BNTC) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Benitec Biopharma EPS (Basic) Related Terms

Benitec Biopharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Benitec Biopharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Benitec Biopharma EPS (Basic) Chart

Benitec Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -54.91 -37.88 -14.12 -1.22 -1.05

Benitec Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.38 -0.21 -0.22 -0.26 -0.24
BNTC
34GF Score
Benitec Biopharma Inc BNTC
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Benitec Biopharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Benitec Biopharma's Basic EPS for the fiscal year that ended in Jun. 2025 is calculated as

Basic EPS (A: Jun. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-37.917-0)/36.209
=-1.05

Benitec Biopharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-11.935-0)/49.386
=-0.24

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.93 mean?
Benitec Biopharma (BNTC) has a EPS (Basic) of $-0.93 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Benitec Biopharma and its competitors.
Is Benitec Biopharma's EPS (Basic) too high?
Benitec Biopharma's current EPS (Basic) is $-0.93. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's EPS (Basic) compare to OABI and FBRX?
Benitec Biopharma's EPS (Basic) of $-0.93 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Benitec Biopharma and its competitors. Benitec Biopharma's current EPS (Basic) is $-0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (BNTC) has a current EPS (Basic) of $-0.93. The current EPS (Basic) is $-0.93. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Benitec Biopharma (BNTC), the current EPS (Basic) is $-0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Benitec Biopharma Business Description

Address 3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score

Get the complete analysis for BNTC

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.07
Price